PriceTargets.com logo

Oncternal Therapeutics - ONCT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $4.10
  • Forecasted Upside: 1,231.17%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.31 As of 10/2/2023 01:00 AM ET
▲ +0.01 (3.36%)

This chart shows the closing price for ONCT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oncternal Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ONCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ONCT

Analyst Price Target is $4.10
▲ +1,231.17% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Oncternal Therapeutics in the last 3 months. The average price target is $4.10, with a high forecast of $9.00 and a low forecast of $1.30. The average price target represents a 1,231.17% upside from the last price of $0.31.

This chart shows the closing price for ONCT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 contributing investment analysts is to hold stock in Oncternal Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
4/10/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
7/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
1/5/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
4/5/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
7/4/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
9/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/18/2023HC WainwrightUpgradeNeutral ➝ Buy$2.00Low
9/7/2023Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$1.30Low
4/6/2023Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
4/4/2023Brookline Capital AcquisitionReiterated RatingBuy ➝ HoldLow
4/4/2023Maxim GroupDowngradeBuy ➝ HoldLow
4/4/2023Cantor FitzgeraldLower TargetOverweight$4.00 ➝ $1.30Low
4/4/2023HC WainwrightDowngradeBuy ➝ NeutralLow
4/4/2023OppenheimerDowngradeOutperform ➝ Market PerformLow
4/3/2023Brookline Capital ManagementDowngradeBuy ➝ HoldLow
3/22/2023OppenheimerLower TargetOutperform$14.00 ➝ $9.00Low
3/14/2023HC WainwrightReiterated RatingBuy$7.00Low
3/9/2023Brookline Capital ManagementReiterated RatingBuyLow
12/22/2022Cantor FitzgeraldInitiated CoverageOverweight$4.00Low
8/10/2022HC WainwrightLower TargetBuy$8.00 ➝ $7.00Low
5/10/2022Maxim GroupInitiated CoverageBuyMedium
2/24/2022BTIG ResearchInitiated CoverageBuy$5.00High
9/21/2021HC WainwrightReiterated RatingBuy$9.00High
4/16/2021HC WainwrightReiterated RatingBuy$9.00Medium
4/6/2021OppenheimerInitiated CoverageOutperform$14.00High
3/30/2021Brookline Capital ManagementReiterated RatingBuy$16.00High
3/30/2021Brookline Capital AcquisitionInitiated CoverageBuy$16.00High
3/12/2021HC WainwrightBoost TargetBuy$8.00 ➝ $9.00High
2/23/2021Northland SecuritiesInitiated CoverageOutperform$21.00High
11/12/2020HC WainwrightReiterated RatingBuyLow
9/21/2020HC WainwrightReiterated RatingBuy$8.00Low
8/10/2020HC WainwrightInitiated CoverageBuy$8.00Medium
(Data available from 10/3/2018 forward)

News Sentiment Rating

-0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/6/2023
  • 3 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/5/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/5/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/4/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/4/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/3/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/2/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/2/2023

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Oncternal Therapeutics logo
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
Read More

Today's Range

Now: $0.31
Low: $0.30
High: $0.33

50 Day Range

MA: $0.33
Low: $0.29
High: $0.41

52 Week Range

Now: $0.31
Low: $0.26
High: $1.33

Volume

45,591 shs

Average Volume

151,201 shs

Market Capitalization

$18.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Oncternal Therapeutics?

The following equities research analysts have issued stock ratings on Oncternal Therapeutics in the last year: Brookline Capital Acquisition Corp., Brookline Capital Management, Cantor Fitzgerald, HC Wainwright, Maxim Group, Oppenheimer Holdings Inc., and StockNews.com.
View the latest analyst ratings for ONCT.

What is the current price target for Oncternal Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Oncternal Therapeutics in the last year. Their average twelve-month price target is $4.10, suggesting a possible upside of 1,231.2%. Oppenheimer Holdings Inc. has the highest price target set, predicting ONCT will reach $9.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $1.30 for Oncternal Therapeutics in the next year.
View the latest price targets for ONCT.

What is the current consensus analyst rating for Oncternal Therapeutics?

Oncternal Therapeutics currently has 5 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ONCT, but not buy more shares or sell existing shares.
View the latest ratings for ONCT.

What other companies compete with Oncternal Therapeutics?

Other companies that are similar to Oncternal Therapeutics include Virios Therapeutics, Hepion Pharmaceuticals, Alzamend Neuro, Mustang Bio and Acasti Pharma. Learn More about companies similar to Oncternal Therapeutics.

How do I contact Oncternal Therapeutics' investor relations team?

Oncternal Therapeutics' physical mailing address is 12230 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company's listed phone number is (858) 434-1113 and its investor relations email address is [email protected]. The official website for Oncternal Therapeutics is www.oncternal.com. Learn More about contacing Oncternal Therapeutics investor relations.